Dr. Berry studies the humoral immune response to malaria following natural infection and malaria vaccination. She co-leads the Immunoepidemiology and Pathogenesis Unit within the Malaria Research Program with Dr. Travassos. She uses protein and peptide microarrays to simultaneously profile the antibody reactivity to hundreds to thousands of malaria proteins and peptides. Her goal is to identify signatures of antibody responses that are associated with protection from malaria illness to inform next generation malaria vaccine design.
Dr. Berry is a member of the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine and Treatment Evaluation Unit (VTEU) network of investigators. Recent NIAID clinical studies have included trials of pandemic and seasonal influenza vaccines, a study of concurrent use of both licensed brands of rotavirus vaccines within the same schedule, and a study of the immunogenicity of Human Papilloma Virus vaccine when given outside of the recommended schedule.
Dr. James Campbell’s research interests include clinical trials of vaccines in all age groups, epidemiology of vaccine-preventable diseases, and HIV prevention. He has performed trials of vaccines against many organisms, including Neisseria meningitidis, Bacillus anthracis, seasonal influenza, pandemic influenza, and smallpox. Dr. Campbell has overseen trials for innovative vaccine administration techniques and coordinated vaccine trials of childhood immunizations at three pediatric clinic vaccine sites in Maryland.
He helped establish and oversee a microbiology laboratory at the pediatric hospital in Bamako, Mali where they investigated the causes of invasive bacterial infections, particularly Streptococcus pneumoniae and Haemophilus influenzae type b. From 2007 to 2012, he was a medical officer/epidemiologist with CDC’s Division of HIV/AIDS Prevention and the in-country Associate Director for Science in Kampala, Uganda. Dr. Campbell’s work in Uganda included HIV prevention trials and research on Nodding Syndrome and other outbreaks.
Dr. Kotloff’s research focuses on the epidemiology of infectious diseases and their prevention with the use of vaccines in both the U.S. and developing countries. She is Principal Investigator (PI) of the Vaccine Treatment and Evaluation Unit at the UMSOM’s Center for Vaccine Development funded by the National Institute of Allergy and Infectious Disease. This contract funds vaccines and treatments against infectious diseases of public health importance.
Dr. Kotloff has led numerous clinical trials to evaluate vaccines against a wide range of infections, including group A streptococcus, Shigella, and influenza. She is also PI of three grants funded by the Bill & Melinda Gates Foundation to study prevention and treatment of diarrheal diseases and to conduct intensive studies of the causes of death among infants and children in developing countries. In collaboration with Centre pour le Développement des Vaccins – Mali (CVD-Mali), one of her current studies aims to measure the impact of rotavirus vaccine introduction on the etiology and outcome of moderate-to-severe diarrhea among infants and children living in three African countries. Another recent study conducted at CVD-Mali focused on population-based surveillance of moderate to severe diarrhea using multiplex polymerase chain reaction assays, immunoassays, and bacteriology.
She participates in numerous international advisory committees for the Bill & Melinda Gates Foundation and the World Health Organization.
Dr. Laufer is a pediatric infectious disease specialist, with a primary research interest in malaria and global child health. She has conducted research, clinical care and professional education in several resource-limited countries, but has dedicated the past 15 years to working in Malawi. She and her research team use clinical and laboratory research to develop and evaluate interventions to decrease the burden of malaria in sub-Saharan Africa. Dr. Laufer received an NIH Fogarty International Center grant in 2016, which supports training in molecular epidemiology, biostatistics and vector biology to promote efforts to eliminate malaria and the other infectious diseases that threaten the health of children in the region. She currently serves as Principal Investigator for clinical trials and epidemiological studies throughout Malawi.
Her current research focuses on malaria during pregnancy and its impact on infants, the interaction between HIV and malaria and identifying reservoirs of malaria transmission. Her laboratory at the University of Maryland explores the application of molecular epidemiology tools to address critical issues related to malaria pathogenesis, disease burden and drug resistance.
Dr. Laufer serves as the Associate Director for the Center for Vaccine Development and Global Health (CVD). She leads outreach efforts throughout the School of Medicine and the entire University of Maryland campus to support and promote global health research.
Dr. Laurens is a pediatric infectious disease specialist with a primary research interest in malaria and antimalarial immunity. He conducts studies at the Center for Vaccine Development (CVD) in Baltimore and at international sites in Burkina Faso, Mali, and Malawi. Dr. Laurens evaluates malaria vaccines and therapeutics, to study the interaction of HIV and malaria and to investigate the acquisition of antimalarial immunity. The broad goal of Dr. Laurens’ research is to illuminate the mechanisms of immunity to malaria with the aim to inform development of malaria vaccines and therapeutics.
He has served as a consultant to the WHO Initiative for Vaccine Research to develop guidelines for the design and conduct of malaria challenge trials, including guidelines for microscopy diagnostics and clinical management. Dr. Laurens has significant experience in vaccine trials in limited resource settings, including first-in-human studies conducted under IND with safety endpoints; he played a critical role in the clinical development plan of Sanaria’s PfSPZ Vaccine from the very first-in-human clinical trial at University of Maryland Baltimore to a current dose escalation study in malaria-exposed adults in Burkina Faso.
Dr. Laurens is also involved in a pediatric typhoid conjugate vaccine trial in Malawi, which is the first of its kind on the African continent. He also helps to lead a complementary study of pediatric typhoid conjugate vaccine in infants and children in Burkina Faso.
Dr. Laurens directs the Pediatric Infectious Diseases Fellowship Program at the University of Maryland School of Medicine, where the most promising pediatric infectious disease physician-scientists are trained in clinical care and research.
Dr. McArthur’s research interests span the spectrum of vaccine development to include pre-clinical studies, translational immunology, and clinical trials. Her overarching research goal is to advance vaccine development to prevent infection in resource-limited countries. For almost a decade, Dr. McArthur has focused on interactions between pathogens and the host immune response – identifying immunological correlates of protection following vaccination.
Dr. McArthur works with a number of pathogens of global public health importance, including enteric bacteria such as Salmonella Typhi, Enterotoxigenic Escherichia coli (ETEC), and Vibrio cholerae, as well as arboviruses, such as Zika, dengue, and yellow fever viruses. While many diseases caused by these pathogens are rare in the United States, they continue to cause significant morbidity, mortality, and economic hardship in low and middle-income countries.
As the Principal Investigator (PI) for a Robert Wood Johnson Foundation, Harold Amos Medical Faculty Development Program Career Development Award, Dr. McArthur investigates the role of T cells in protection against cholera. She is using data from a vaccination and wild-type challenge clinical trial conducted at the CVD to perform in-depth immunophenotyping of V. cholerae-responsive T cell subsets (e.g., effector memory CD4+ T cells, circulating T follicular helper cells – cTfh) using mass cytometry. She also explores the mechanisms by which T cells provide B cell “help” in hopes of identifying correlates of vaccine-induced protection.
Dr. McArthur also researches immunological responses induced by flaviviruses, including Zika and dengue, and vaccine development against these viruses. Zika virus is a mosquito-borne flavivirus that inflicts devastating neurological defects on infants born to mothers infected during pregnancy. This emerging virus has spread geographically and may continue to affect naïve populations. To halt further cases an effective vaccine is urgently needed. Dr. McArthur is the site PI for a National Institutes of Health (NIH) Phase I/Ib clinical trial to evaluate the safety and immunogenicity of a candidate Zika virus DNA vaccine, a collaborative project with the NIH Vaccine Research center and Emory University.
Dr. Tapia’s research focuses primarily on the epidemiology of vaccine-preventable diseases in Mali and the development of vaccines to address these diseases. In conjunction with the team at CVD-Mali (Centre pour le Développement des Vaccins – Mali), headed by Dr. Samba Sow, she has conducted and participated in the following vaccine-development activities:
In addition to assisting in the development of these important vaccines, Dr. Tapia and the CVD-Mali team have described the epidemiology of pediatric infections with Haemophilus influenzae type b and Streptococcus pneumoniae. These data have led to the introduction of life-saving vaccines (Hib conjugate vaccine and 13-valent pneumococcal conjugate vaccine) into the Malian Expanded Programme on Immunization.
Dr. Travassos is a pediatric infectious diseases specialist and member of the Center for Vaccine Development and Global Health’s Malaria Research Group. He co-leads the Immunoepidemiology and Pathogenesis Unit within the Malaria Research Program with Dr. Berry. His research focuses on malaria pathogenesis and epidemiology, with a focus on cerebral malaria and other forms of severe malaria. Dr. Travassos is particularly interested in malaria parasite variant surface antigens and their contribution to the development of cerebral malaria. He employs novel immune techniques such as microarray analysis to probe the human response to P. falciparum malaria.
Dr. Travassos currently studies cerebral malaria in Mali, and this project focuses on novel genomic and proteomic approaches with the use of a new animal model to measure the association between particular variant surface antigens and the development of cerebral malaria and also protective natural immunity. His research also includes work in Ethiopia assessing vaccine coverage through the use of serosurveys.
TRAINING PROGRAM DIRECTOR:
Matthew Laurens, MD, MPH
DIVISION DIRECTOR OF INFECTIOUS DISEASES:
Karen Kotloff, MD
MAJOR FEATURES OF TRAINING PROGRAM:
The Division of Infectious Diseases and Tropical Pediatrics of the University of Maryland School of Medicine has a longstanding comprehensive clinical and research training program. Clinical training takes place at the Maryland Hospital for Children, part of the University of Maryland Medical Center (UMMC). The hospital provides all pediatric and surgical subspecialty services, making our infectious diseases clinical service diverse and engaging. The Division of Pediatric Diseases and Tropical Pediatrics is part of the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD), recognized internationally for expertise in all aspects of vaccine development both domestic and international from basic science vaccinology research, infectious diseases epidemiology and burden of disease, to cutting-edge immunology and to post-licensure studies. The CVD provides a rich, international training environment with research support for fellows available through an NIH T32 Training Grant in Vaccinology. Trainees are mentored by teams of leaders in their respective fields, and advance to positions in academics, CDC, NIH, FDA, clinical infectious diseases, industry, and international NGOs.
University of Maryland Medical Center
AVAILABLE FELLOWSHIP POSITIONS: Yearly
Number of trainees completing program in the last 5 years: 4
TRAINING FOR: ☒ MD ☒ DO ☒ MD, PhD
FUNDING ENSURED FOR ALL 3 YEARS: YES
VISAS ACCEPTED: ☒ J1
IS COMPLETION OF PEDIATRIC RESIDENCY TRAINING IN THE U.S. OR CANADA A REQUIREMENT? YES
THE PROGRAM OFFERS THE FOLLOWING TRAINING
Program provides substantial experience for trainee in:
Opportunity to fulfill the ABP requirements for scholarly activity is available in the following general areas:
Documented liaison exists offering opportunities for research experience in the laboratory of investigator(s) who is/are not faculty of the section.
Program offers the opportunity to obtain a Master’s degree in a field such as Public Health, Education, Clinical Sciences or Epidemiology (assuming appropriate arrangements are made).
Graduate School courses are available to trainee (assuming appropriate arrangements are made).
Program includes ABP-required core curricula in scholarly activities in didactic lecture and/or experiential courses for fellows (epidemiology, statistics, research design, quality improvement and academic careers).
Program has an NIH-sponsored grant.
The Infectious Diseases Service is the primary care provider for HIV infected children and adolescents.